Small MoleculesMar 13, 2025
Facilitating PROTAC Drugs Development with Innovative Processes
The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.
Biologics and ConjugatesFeb 10, 2025
Efficacy and Safety - Guidelines for Clinical In-use Stability Studies of ADCs
Antibody-drug conjugates (ADCs) consist of three parts: antibody, linker, and payload. This special combination enables ADCs to selectively target tumor cells and release cytotoxic drugs, but they face many stability challenges during manufacture, storage, and clinical use. In this paper, the drug product development team at Porton (hereinafter referred to as "we") discusses the necessary clinical in-use stability studies for ADCs.
Case Studies & WhitepapersJan 06, 2025
Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development
Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development
Small MoleculesJan 06, 2025
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Case Studies & WhitepapersJan 03, 2025
Agile and Fast：Enabling Rapid Market Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months
Enabling Rapid Market Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months
Biologics and ConjugatesNov 27, 2024
Overview and Case Study of Antibody Oligonucleotide Conjugates (AOC)
In the field of biomedical science, technological changes are common and constantly evolving. In recent years, antibody oligonucleotide conjugates (AOCs) have attracted considerable attention in the industry as an innovative and advanced biomedical method, and more and more domestic and foreign biopharmaceutical companies have participated in the research and application of AOCs. Because AOC combines the advantages of oligonucleotide technology and antibodies, it is considered to have the potential to provide precise targeted therapy and is expected to bring about a revolution in the biomedical field.
Small MoleculesNov 25, 2024
Co-processing: Co-Precipitation Technology (CPT) for the Enhancement of Flowability and Bulk Density
Formulating compressed tablets is one of the most widely used oral solid form dosages. However, a vital first step is choosing a suitable manufacturing approach and the right excipients to support the desired therapeutic effect.
Biologics and ConjugatesNov 18, 2024
An ADC's Path to Market-Analysis of Difficulties and Key Points in ADC Process Scale up
An Antibody-Drug Conjugate (ADC) is a novel therapeutic agent which can deliver a highly-potent traditional small molecule drug to a specific site or cell within the body. It is formed when an active drug (the payload) is connected to an antibody using a linker. The complex is referred to as an ADC and it uses the cellular specificity of antibodies to direct the payload and deliver to the active disease site within the cell. This enables ADCs to selectively treat cancer cells, tumor microenvironments, or other target cells, while reducing systemic, off-target toxicity. This targeted delivery of ADC agents has shown great promise and explosive growth in recent years.
Small MoleculesNov 09, 2024
ENT-03 GRC Poster
ENT-03 was predicted to be the mammalian equivalent of trodusquemine, based on knowledge of the bile acids produced in mammals, such as 7-HOCA. The individual C-25 isomers of ENT-03 were prepared and both detected in mouse brain. Trodusquemine and ENT-03 have both demonstrated dramatic effects in obesity and insulin resistance. (25S)-ENT-03 was selected for development for the treatment of diabetes and obesity.
